Antimicrobial Susceptibility Profiles of Commensal Escherichia coli Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023
Antibiotics · 16.03.2025 · 14 (3) · 305
DOI: 10.3390/antibiotics14030305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 16.03.2025. Verfasst von Ákos Jerzsele und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Recovery Fund.
Abstract (Originalsprache)
Background
The global spread of antimicrobial resistance (AMR) has prompted the critical importance of regular monitoring. Escherichia coli, a widely distributed facultative anaerobic pathogen, is significant both in terms of the clinical diseases that it causes and as a reservoir of antimicrobial resistance, with notable implications for both animal and public health. Within the poultry industry, the turkey sector is an emerging and internationally significant branch.
Methods
Our objective was to assess the antimicrobial resistance profile of commensal Escherichia coli strains isolated from large-scale turkey flocks in Hungary using minimum inhibitory concentration (MIC) determination.
Results
A total of 470 isolates were analyzed, revealing that 61.5% of the strains were resistant to amoxicillin, while 18.5% were resistant to amoxicillin–clavulanic acid. The resistance observed against enrofloxacin (62.8%) and ceftriaxone (24%) is concerning. Comparison with human resistance data showed a similar resistance rate for amoxicillin and ampicillin, as well as amoxicillin–clavulanic acid and cephalosporins. However, for other active substances, the situation was significantly worse in veterinary medicine.
Conclusions
The lower resistance to amoxicillin–clavulanic acid indicates that most strains are β-lactamase producers. Our findings underscore the necessity of regular and comprehensive surveillance, which can establish temporal trends over time. Incorporating data on antibiotic usage into future studies could facilitate the exploration of relevant correlations. Additionally, the next-generation sequencing of multidrug-resistant strains could help elucidate the genetic basis of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary.
- National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary.
- Department of Animal Hygiene, Herd Health and Mobile Clinic, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary.
- Poultry-Care Kft., Lehel út 21, H-5052 Újszász, Hungary.
ORCID-Profile: Ákos Jerzsele, Ádám Kerek, László Kovács
Förderung
- National Recovery Fund
Zitieren
APA
Jerzsele, Á., Kerek, Á., Barnácz, F., Csirmaz, B., Szabó, Á., & Kovács, L. (2025). Antimicrobial Susceptibility Profiles of Commensal Escherichia coli Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023. Antibiotics, 14(3), 305. https://doi.org/10.3390/antibiotics14030305
Vancouver
Jerzsele Á, Kerek Á, Barnácz F, Csirmaz B, Szabó Á, Kovács L. Antimicrobial Susceptibility Profiles of Commensal Escherichia coli Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023. Antibiotics. 2025;14(3):305. doi:10.3390/antibiotics14030305
BibTeX
@article{Jerzsele2025,
author = {Jerzsele, Ákos and Kerek, Ádám and Barnácz, Franciska and Csirmaz, Bence and Szabó, Ábel and Kovács, László},
title = {Antimicrobial Susceptibility Profiles of Commensal Escherichia coli Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {3},
pages = {305},
doi = {10.3390/antibiotics14030305}
}
EUVIMED